Cardiology

Here is the reality check we need this week over coffee: targeting systemic inflammation via myeloperoxidase (MPO) in heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) just hit a major wall, while the infrastructure backing our rapid rollout of clinical AI in cardiology is showing fragile operational seams.

First, the major clinical readout: A randomized, double-blind Phase 2b trial published in Nature Medicine evaluated mitiperstat—an oral, irreversible myeloperoxidase inhibitor intended to dampen neutrophil-driven vascular inflammation and endothelial dysfunction—in patients with HFpEF and HFmrEF (LVEF ≥40%). Despite compelling preclinical data and early-phase biomarker suppression, mitiperstat failed to show any statistically significant improvement in primary functional endpoints, including 6-minute walk distance (6MWD) change and Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary scores at 12 to 24 weeks compared to placebo. MPO inhibition produced measurable target engagement (lowering systemic fluorodeoxyglucose vascular uptake and serum active MPO levels), but this biochemical hit completely failed to translate into hemodynamic relief, functional capacity gains, or reduction in NT-proBNP levels.

What does this mean for our clinical practice? If you are treating HFpEF/HFmrEF patients, do not expect neutrophil-targeted anti-inflammatory biologics or small molecules to join our armamentarium anytime soon. SGLT2 inhibitors (empagliflozin, dapagliflozin) remain our non-negotiable, guideline-directed standard of care for reducing cardiovascular death and HF hospitalizations, along with finerenone and GLP-1 receptor agonists for the cardiometabolic phenotype. This negative trial reinforces that HFpEF is not a monolithic inflammatory condition; unselected dampening of upstream neutrophil degranulation does not reverse established myocardial stiffness, microvascular rarefaction, or impaired ventricular relaxation.

Simultaneously, two reports in IEEE Spectrum and MIT Technology Review highlight a mounting crisis for digital cardiology and hospital operations: AI compute supply chains and grid vulnerability. Our field relies heavily on low-latency, real-time AI inference—such as automated STEMI detection alerts from 12-lead ECGs, cloud-based CT-FFR rendering (e.g., HeartFlow), and inpatient ambulatory telemetry monitoring. Recent regional power grid instabilities and transformer failures affecting major multi-tenant data center hubs in Northern Virginia, alongside European AI chip bottlenecks, emphasize that centralized cloud-dependent cardiology algorithms pose an emergent single point of clinical failure when localized offline redundancy is absent.

Key limitations of this week's data include the Phase 2b nature of the mitiperstat trial: its sample size was powered strictly for intermediate functional endpoints (KCCQ, 6MWD) rather than hard clinical outcomes like HF rehospitalization or all-cause mortality, and it did not stratify patients by baseline systemic inflammatory endotypes (e.g., elevated hs-CRP or myeloperoxidase index). Regarding AI deployment, health systems routinely lack redundant, local-edge computing architectures to ensure automated ECG triage and cath lab workflows continue running during wide-area data center blackouts.

What to watch over the next 12–18 months: First, biomarker-driven HFpEF phenotyping algorithms (integrating transcriptomics and machine learning) to prospectively identify the 15–20% subset of HFpEF patients who actually harbor inflammatory microvascular disease before initiating targeted immune-modulating trials. Second, migration of critical cardiology AI tools—specifically bedside 12-lead ECG STEMI detection and point-of-care ultrasound (POCUS) ejection fraction quantification—from remote centralized clouds to native on-device/edge silicon, mitigating cloud outage vulnerabilities.